[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fXRV7N7EPUrdzVyU9usMQZg8epD0G_JJ0UwJFfgvWg6A":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":37,"phaseBuckets":73,"rows":80},"Centre Francois Baclesse",[4,6],"Centre Francois Baclesse, Luxembourg",117,false,32,9,14517,8,88,[15,18,21,24,27,30,32,34],{"name":16,"count":17},"Breast Cancer",20,{"name":19,"count":20},"Cancer",15,{"name":22,"count":23},"Head and Neck Cancer",6,{"name":25,"count":26},"Ovarian Cancer",4,{"name":28,"count":29},"Radiation Toxicity",3,{"name":31,"count":29},"Radiotherapy",{"name":33,"count":29},"Oncology",{"name":35,"count":36},"Endometrial Cancer",2,[38,43,48,53,58,63,68],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02701088","Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life","2021-06-25","5Fluorouracile and Mitomycin-C",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04678362","TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma","2023-07-28","Talazoparib + Avelumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03212742","Phase I\u002FIIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients","2026-09-13","Olaparib",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06792721","MEASUREMENT OF CIRCULATING MUTATION BURDEN","2027-07-15","Mutation Burden cfMB analysis",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT07028125","Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma","2028-10","cabozantinib and nivolumab",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04290663","Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up","2031-02","Systematic RAI-treatment",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06152731","HRD Tests for Ovarian cancER","2031-06","tests to determine HRD status",[74,75,76,77,78,79],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[81,108,131,150,173,194,218,236,262,291,309,327,362,386,411,429,456,474,505,523,550,574,600,618,645,670,695,718,736,761,790,815,849,874,899],{"intervention":62,"totalTrials":82,"cells":83},1,{"EARLY_PHASE1":84,"PHASE1":87,"PHASE2":89,"PHASE3":91,"PHASE4":93,"NA":106},{"trials":85,"activeCount":86},[],0,{"trials":88,"activeCount":86},[],{"trials":90,"activeCount":86},[],{"trials":92,"activeCount":86},[],{"trials":94,"activeCount":82,"soonestReadout":61},[95],{"nctId":59,"briefTitle":60,"status":96,"phases":97,"primaryCompletion":61,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":105},"RECRUITING",[78],"2029-01","2025-10-01",83,[102,103,104],"Renal Cell Carcinoma (Kidney Cancer)","Metastatic Renal Cell Carcinoma","Locally Advanced",[62],{"trials":107,"activeCount":86},[],{"intervention":67,"totalTrials":82,"cells":109},{"EARLY_PHASE1":110,"PHASE1":112,"PHASE2":114,"PHASE3":116,"PHASE4":127,"NA":129},{"trials":111,"activeCount":86},[],{"trials":113,"activeCount":86},[],{"trials":115,"activeCount":86},[],{"trials":117,"activeCount":82,"soonestReadout":66},[118],{"nctId":64,"briefTitle":65,"status":96,"phases":119,"primaryCompletion":66,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":126},[77],"2033-02","2020-03-02",476,[124,125],"Thyroid Cancer","Intermediate Risk",[67],{"trials":128,"activeCount":86},[],{"trials":130,"activeCount":86},[],{"intervention":72,"totalTrials":82,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":144,"PHASE4":146,"NA":148},{"trials":134,"activeCount":86},[],{"trials":136,"activeCount":86},[],{"trials":138,"activeCount":82,"soonestReadout":71},[139],{"nctId":69,"briefTitle":70,"status":96,"phases":140,"primaryCompletion":71,"completion":71,"start":141,"enrollment":13,"conditions":142,"interventions":143},[76],"2024-02-15",[25],[72],{"trials":145,"activeCount":86},[],{"trials":147,"activeCount":86},[],{"trials":149,"activeCount":86},[],{"intervention":42,"totalTrials":82,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":167,"PHASE4":169,"NA":171},{"trials":153,"activeCount":86},[],{"trials":155,"activeCount":86},[],{"trials":157,"activeCount":82,"soonestReadout":41},[158],{"nctId":39,"briefTitle":40,"status":159,"phases":160,"primaryCompletion":41,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},"ACTIVE_NOT_RECRUITING",[76],"2025-12","2015-12",71,[165],"Locally Advanced Anal Canal Cancer",[42],{"trials":168,"activeCount":86},[],{"trials":170,"activeCount":86},[],{"trials":172,"activeCount":86},[],{"intervention":47,"totalTrials":82,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":188,"PHASE4":190,"NA":192},{"trials":176,"activeCount":86},[],{"trials":178,"activeCount":86},[],{"trials":180,"activeCount":82,"soonestReadout":46},[181],{"nctId":44,"briefTitle":45,"status":96,"phases":182,"primaryCompletion":46,"completion":161,"start":183,"enrollment":184,"conditions":185,"interventions":187},[76],"2021-06-01",50,[186],"Urothelial Carcinoma",[47],{"trials":189,"activeCount":86},[],{"trials":191,"activeCount":86},[],{"trials":193,"activeCount":86},[],{"intervention":52,"totalTrials":82,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":212,"PHASE4":214,"NA":216},{"trials":197,"activeCount":86},[],{"trials":199,"activeCount":86},[],{"trials":201,"activeCount":82,"soonestReadout":51},[202],{"nctId":49,"briefTitle":50,"status":159,"phases":203,"primaryCompletion":51,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":210},[75,76],"2026-12-31","2017-09-04",91,[208,31,209],"Malignant Gliomas","PARP Inhibitor",[52,211],"Temozolomide",{"trials":213,"activeCount":86},[],{"trials":215,"activeCount":86},[],{"trials":217,"activeCount":86},[],{"intervention":211,"totalTrials":82,"cells":219},{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":230,"PHASE4":232,"NA":234},{"trials":221,"activeCount":86},[],{"trials":223,"activeCount":86},[],{"trials":225,"activeCount":82,"soonestReadout":51},[226],{"nctId":49,"briefTitle":50,"status":159,"phases":227,"primaryCompletion":51,"completion":204,"start":205,"enrollment":206,"conditions":228,"interventions":229},[75,76],[208,31,209],[52,211],{"trials":231,"activeCount":86},[],{"trials":233,"activeCount":86},[],{"trials":235,"activeCount":86},[],{"intervention":57,"totalTrials":82,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":239,"activeCount":86},[],{"trials":241,"activeCount":86},[],{"trials":243,"activeCount":86},[],{"trials":245,"activeCount":86},[],{"trials":247,"activeCount":86},[],{"trials":249,"activeCount":82,"soonestReadout":56},[250],{"nctId":54,"briefTitle":55,"status":96,"phases":251,"primaryCompletion":56,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":261},[],"2027-12-30","2025-07-04",30,[256,257,258,259,260],"Breast Carcinoma","Genetic Predisposition to Cancer","BRCA Mutation","cfMB","Mutation Burden",[57],{"intervention":263,"totalTrials":82,"cells":264},"ARM A : IV iron + epoietin zeta",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":289},{"trials":266,"activeCount":86},[],{"trials":268,"activeCount":86},[],{"trials":270,"activeCount":86},[],{"trials":272,"activeCount":86},[],{"trials":274,"activeCount":86},[275],{"nctId":276,"briefTitle":277,"status":278,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":286},"NCT02213653","Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency","TERMINATED",[78],"2014-11","2013-04",24,[284,285],"Solid Cancer Metastatic Disease","Lymphoid Disease",[263,287,288],"ARM B: IV iron + epoietin zeta sequence","ARM C : single epoietin zeta",{"trials":290,"activeCount":86},[],{"intervention":287,"totalTrials":82,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":301,"NA":307},{"trials":294,"activeCount":86},[],{"trials":296,"activeCount":86},[],{"trials":298,"activeCount":86},[],{"trials":300,"activeCount":86},[],{"trials":302,"activeCount":86},[303],{"nctId":276,"briefTitle":277,"status":278,"phases":304,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":305,"interventions":306},[78],[284,285],[263,287,288],{"trials":308,"activeCount":86},[],{"intervention":288,"totalTrials":82,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":325},{"trials":312,"activeCount":86},[],{"trials":314,"activeCount":86},[],{"trials":316,"activeCount":86},[],{"trials":318,"activeCount":86},[],{"trials":320,"activeCount":86},[321],{"nctId":276,"briefTitle":277,"status":278,"phases":322,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":323,"interventions":324},[78],[284,285],[263,287,288],{"trials":326,"activeCount":86},[],{"intervention":328,"totalTrials":36,"cells":329},"filgrastim",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":348,"PHASE4":358,"NA":360},{"trials":331,"activeCount":86},[],{"trials":333,"activeCount":86},[],{"trials":335,"activeCount":86},[336],{"nctId":337,"briefTitle":338,"status":339,"phases":340,"primaryCompletion":341,"start":342,"enrollment":343,"conditions":344,"interventions":347},"NCT00771433","G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer","COMPLETED",[76],"2011-05","2007-10",120,[16,345,346],"Chemotherapeutic Agent Toxicity","Neutropenia",[328],{"trials":349,"activeCount":86},[350],{"nctId":351,"briefTitle":352,"status":339,"phases":353,"primaryCompletion":341,"start":342,"enrollment":354,"conditions":355,"interventions":357},"NCT00770172","G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy",[77],140,[345,346,356],"Unspecified Adult Solid Tumor, Protocol Specific",[328],{"trials":359,"activeCount":86},[],{"trials":361,"activeCount":86},[],{"intervention":363,"totalTrials":82,"cells":364},"Ialuset®",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":382,"NA":384},{"trials":366,"activeCount":86},[],{"trials":368,"activeCount":86},[],{"trials":370,"activeCount":86},[],{"trials":372,"activeCount":86},[373],{"nctId":374,"briefTitle":375,"status":339,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT01520701","Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy",[77],"2022-10","2012-02",125,[22],[363],{"trials":383,"activeCount":86},[],{"trials":385,"activeCount":86},[],{"intervention":387,"totalTrials":82,"cells":388},"ERLOTINIB WITH CHEMOTHERAPY",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":407,"NA":409},{"trials":390,"activeCount":86},[],{"trials":392,"activeCount":86},[],{"trials":394,"activeCount":86},[],{"trials":396,"activeCount":86},[397],{"nctId":398,"briefTitle":399,"status":278,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":23,"conditions":403,"interventions":405},"NCT02178397","A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR",[77],"2015-09","2014-06",[404],"NSCLC Patients With EGFR Activating Mutation",[387,406],"CHEMOTHERAPY ONLY",{"trials":408,"activeCount":86},[],{"trials":410,"activeCount":86},[],{"intervention":406,"totalTrials":82,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":425,"NA":427},{"trials":414,"activeCount":86},[],{"trials":416,"activeCount":86},[],{"trials":418,"activeCount":86},[],{"trials":420,"activeCount":86},[421],{"nctId":398,"briefTitle":399,"status":278,"phases":422,"primaryCompletion":401,"completion":401,"start":402,"enrollment":23,"conditions":423,"interventions":424},[77],[404],[387,406],{"trials":426,"activeCount":86},[],{"trials":428,"activeCount":86},[],{"intervention":430,"totalTrials":82,"cells":431},"TOPOTECAN",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":433,"activeCount":86},[],{"trials":435,"activeCount":86},[],{"trials":437,"activeCount":86},[438],{"nctId":439,"briefTitle":440,"status":278,"phases":441,"start":442,"enrollment":443,"conditions":444,"interventions":448},"NCT00888810","Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer",[76],"2008-03",39,[19,445,446,447],"Ovarian","Relapse","Chemotherapy",[430,449],"LAPATINIB",{"trials":451,"activeCount":86},[],{"trials":453,"activeCount":86},[],{"trials":455,"activeCount":86},[],{"intervention":449,"totalTrials":82,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":468,"PHASE4":470,"NA":472},{"trials":459,"activeCount":86},[],{"trials":461,"activeCount":86},[],{"trials":463,"activeCount":86},[464],{"nctId":439,"briefTitle":440,"status":278,"phases":465,"start":442,"enrollment":443,"conditions":466,"interventions":467},[76],[19,445,446,447],[430,449],{"trials":469,"activeCount":86},[],{"trials":471,"activeCount":86},[],{"trials":473,"activeCount":86},[],{"intervention":475,"totalTrials":82,"cells":476},"Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":478,"activeCount":86},[],{"trials":480,"activeCount":86},[],{"trials":482,"activeCount":86},[483],{"nctId":484,"briefTitle":485,"status":339,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":497},"NCT04042558","A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+\u002F-Bevacizumab) for Patients With Stage IIIB\u002FIV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies",[76],"2021-10-22","2025-04-09","2019-09-26",150,[492,493,494,495,496],"NSCLC Stage IIIB","NSCLC Stage IV","EGFR Gene Mutation","ALK Gene Rearrangement Positive","ROS1 Gene Mutation",[475,498],"Carboplatin + Pemetrexed + Atezolizumab",{"trials":500,"activeCount":86},[],{"trials":502,"activeCount":86},[],{"trials":504,"activeCount":86},[],{"intervention":498,"totalTrials":82,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":508,"activeCount":86},[],{"trials":510,"activeCount":86},[],{"trials":512,"activeCount":86},[513],{"nctId":484,"briefTitle":485,"status":339,"phases":514,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":515,"interventions":516},[76],[492,493,494,495,496],[475,498],{"trials":518,"activeCount":86},[],{"trials":520,"activeCount":86},[],{"trials":522,"activeCount":86},[],{"intervention":524,"totalTrials":82,"cells":525},"Carboplatin",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":527,"activeCount":86},[],{"trials":529,"activeCount":86},[],{"trials":531,"activeCount":86},[532],{"nctId":533,"briefTitle":534,"status":339,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":543},"NCT03652493","Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway",[76],"2021-04-27","2021-05-21","2018-09-10",16,[541,542],"Castration-resistant Prostate Cancer","Metastasis",[524],{"trials":545,"activeCount":86},[],{"trials":547,"activeCount":86},[],{"trials":549,"activeCount":86},[],{"intervention":447,"totalTrials":82,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":568,"PHASE4":570,"NA":572},{"trials":553,"activeCount":86},[],{"trials":555,"activeCount":86},[],{"trials":557,"activeCount":86},[558],{"nctId":559,"briefTitle":560,"status":561,"phases":562,"primaryCompletion":563,"completion":563,"start":564,"enrollment":86,"conditions":565,"interventions":567},"NCT03199144","Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer","WITHDRAWN",[76],"2021-03-19","2017-04-20",[566],"Pancreatic Neoplasms",[447],{"trials":569,"activeCount":86},[],{"trials":571,"activeCount":86},[],{"trials":573,"activeCount":86},[],{"intervention":575,"totalTrials":82,"cells":576},"Tamoxifen",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":594,"PHASE4":596,"NA":598},{"trials":578,"activeCount":86},[],{"trials":580,"activeCount":86},[],{"trials":582,"activeCount":86},[583],{"nctId":584,"briefTitle":585,"status":278,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":12,"conditions":589,"interventions":592},"NCT02322853","A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors",[76],"2017-04","2015-01",[590,591],"Postmenopausal","Metastatic Breast Cancer",[575,593],"Ralimetinib",{"trials":595,"activeCount":86},[],{"trials":597,"activeCount":86},[],{"trials":599,"activeCount":86},[],{"intervention":593,"totalTrials":82,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":612,"PHASE4":614,"NA":616},{"trials":603,"activeCount":86},[],{"trials":605,"activeCount":86},[],{"trials":607,"activeCount":86},[608],{"nctId":584,"briefTitle":585,"status":278,"phases":609,"primaryCompletion":587,"completion":587,"start":588,"enrollment":12,"conditions":610,"interventions":611},[76],[590,591],[575,593],{"trials":613,"activeCount":86},[],{"trials":615,"activeCount":86},[],{"trials":617,"activeCount":86},[],{"intervention":619,"totalTrials":82,"cells":620},"perioperative treatment",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":622,"activeCount":86},[],{"trials":624,"activeCount":86},[],{"trials":626,"activeCount":86},[627],{"nctId":628,"briefTitle":629,"status":339,"phases":630,"primaryCompletion":631,"completion":632,"start":633,"enrollment":634,"conditions":635,"interventions":638},"NCT04736485","Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)",[76],"2024-03-01","2025-11-27","2021-06-28",67,[636,637],"Gastric Cancer by AJCC V8 Stage","Resectable Carcinoma",[619],{"trials":640,"activeCount":86},[],{"trials":642,"activeCount":86},[],{"trials":644,"activeCount":86},[],{"intervention":646,"totalTrials":82,"cells":647},"Cabozantinib",{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":664,"PHASE4":666,"NA":668},{"trials":649,"activeCount":86},[],{"trials":651,"activeCount":86},[],{"trials":653,"activeCount":86},[654],{"nctId":655,"briefTitle":656,"status":339,"phases":657,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":663},"NCT04205799","Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure",[76],"2023-01-15","2020-01-15",57,[662],"Advanced\u002FMetastatic Cervical Cancer",[646],{"trials":665,"activeCount":86},[],{"trials":667,"activeCount":86},[],{"trials":669,"activeCount":86},[],{"intervention":671,"totalTrials":82,"cells":672},"blood collection",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":689,"PHASE4":691,"NA":693},{"trials":674,"activeCount":86},[],{"trials":676,"activeCount":86},[],{"trials":678,"activeCount":86},[679],{"nctId":680,"briefTitle":681,"status":339,"phases":682,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":688},"NCT01333748","Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and\u002For Ovarian Cancer",[76],"2012-06","2010-04",530,[687],"Hereditary Breast and Ovarian Cancer Syndrome",[671,671],{"trials":690,"activeCount":86},[],{"trials":692,"activeCount":86},[],{"trials":694,"activeCount":86},[],{"intervention":696,"totalTrials":82,"cells":697},"Acetylsalicylic acid + loperamide",{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":712,"PHASE4":714,"NA":716},{"trials":699,"activeCount":86},[],{"trials":701,"activeCount":86},[],{"trials":703,"activeCount":86},[704],{"nctId":705,"briefTitle":706,"status":561,"phases":707,"primaryCompletion":162,"completion":162,"start":708,"enrollment":86,"conditions":709,"interventions":710},"NCT02323516","Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.",[76],"2014-12",[19],[696,711],"diosmectite + loperamide",{"trials":713,"activeCount":86},[],{"trials":715,"activeCount":86},[],{"trials":717,"activeCount":86},[],{"intervention":711,"totalTrials":82,"cells":719},{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":721,"activeCount":86},[],{"trials":723,"activeCount":86},[],{"trials":725,"activeCount":86},[726],{"nctId":705,"briefTitle":706,"status":561,"phases":727,"primaryCompletion":162,"completion":162,"start":708,"enrollment":86,"conditions":728,"interventions":729},[76],[19],[696,711],{"trials":731,"activeCount":86},[],{"trials":733,"activeCount":86},[],{"trials":735,"activeCount":86},[],{"intervention":737,"totalTrials":82,"cells":738},"ABT-263",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":755,"PHASE4":757,"NA":759},{"trials":740,"activeCount":86},[],{"trials":742,"activeCount":86},[],{"trials":744,"activeCount":86},[745],{"nctId":746,"briefTitle":747,"status":339,"phases":748,"primaryCompletion":587,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":754},"NCT02591095","A Study of ABT-263 as Single Agent in Women With Platinum Resistant\u002FRefractory Recurrent Ovarian Cancer",[76],"2019-03","2016-01",47,[753],"Platinum-resistant or Refractory Ovarian Cancer",[737],{"trials":756,"activeCount":86},[],{"trials":758,"activeCount":86},[],{"trials":760,"activeCount":86},[],{"intervention":762,"totalTrials":82,"cells":763},"Essential oils",{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":765,"activeCount":86},[],{"trials":767,"activeCount":86},[],{"trials":769,"activeCount":86},[770],{"nctId":771,"briefTitle":772,"status":339,"phases":773,"primaryCompletion":774,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":783},"NCT04560114","Effect of Inhaled Aromatherapy on Chemo-Induced Nausea Vomiting (NCVI): CINVAROM (Chemotherapy Induced Nausea Vomiting and AROMatherapy)",[76],"2021-09-21","2023-06-30","2020-12-14",96,[779,780,781,782],"Nausea and Vomiting","Aromatherapy","Essential Oil","Suportive Care",[762],{"trials":785,"activeCount":86},[],{"trials":787,"activeCount":86},[],{"trials":789,"activeCount":86},[],{"intervention":791,"totalTrials":82,"cells":792},"Bevacizumab",{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":807,"PHASE3":809,"PHASE4":811,"NA":813},{"trials":794,"activeCount":86},[],{"trials":796,"activeCount":86},[797],{"nctId":798,"briefTitle":799,"status":339,"phases":800,"primaryCompletion":801,"completion":801,"start":802,"enrollment":803,"conditions":804,"interventions":806},"NCT01332929","Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis",[75],"2013-07","2010-06",21,[805],"Metastatic Malignant Neoplasm to Brain",[791],{"trials":808,"activeCount":86},[],{"trials":810,"activeCount":86},[],{"trials":812,"activeCount":86},[],{"trials":814,"activeCount":86},[],{"intervention":816,"totalTrials":36,"cells":817},"Blood sampling",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":826,"NA":828},{"trials":819,"activeCount":86},[],{"trials":821,"activeCount":86},[],{"trials":823,"activeCount":86},[],{"trials":825,"activeCount":86},[],{"trials":827,"activeCount":86},[],{"trials":829,"activeCount":86},[830,840],{"nctId":831,"briefTitle":832,"status":833,"phases":834,"primaryCompletion":835,"completion":835,"start":836,"enrollment":17,"conditions":837,"interventions":839},"NCT04948840","Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis","UNKNOWN",[79],"2024-12-31","2022-04-01",[28,838,16],"Fibrosis",[816],{"nctId":841,"briefTitle":842,"status":339,"phases":843,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":848},"NCT05303129","Prognostic Impact of the Neutrophil\u002FLymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4\u002F6 Inhibitor.",[79],"2024-12-17","2022-05-27",165,[16,591],[816],{"intervention":850,"totalTrials":82,"cells":851},"Hormonotherapy",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":853,"activeCount":86},[],{"trials":855,"activeCount":86},[],{"trials":857,"activeCount":86},[],{"trials":859,"activeCount":86},[],{"trials":861,"activeCount":86},[],{"trials":863,"activeCount":86},[864],{"nctId":865,"briefTitle":866,"status":339,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":870,"conditions":871,"interventions":873},"NCT03420105","Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep",[79],"2020-03-06","2018-01-05",75,[16,872],"Memory Disorders",[850],{"intervention":875,"totalTrials":82,"cells":876},"Blood sample collection",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":878,"activeCount":86},[],{"trials":880,"activeCount":86},[],{"trials":882,"activeCount":86},[],{"trials":884,"activeCount":86},[],{"trials":886,"activeCount":86},[],{"trials":888,"activeCount":86},[889],{"nctId":890,"briefTitle":891,"status":833,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":898},"NCT05433974","Pre-therapeutic Analysis of the Individual Radiosensitivity of Cancer Patients in Luxembourg (APRI-Lux): Prospective National Interventional Study With Minimal Risk",[79],"2024-06-01","2022-10-01",200,[897,19,28],"Radiosensitivity",[875],{"intervention":900,"totalTrials":82,"cells":901},"collection of blood, urine, tumor and ascite samples",{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":903,"activeCount":86},[],{"trials":905,"activeCount":86},[],{"trials":907,"activeCount":86},[],{"trials":909,"activeCount":86},[],{"trials":911,"activeCount":86},[],{"trials":913,"activeCount":86},[914],{"nctId":915,"briefTitle":916,"status":339,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":922},"NCT03831230","Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response",[],"2025-02-27","2019-03-07",250,[25],[900]]